A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
Latest Information Update: 09 May 2025
At a glance
- Drugs Danvilostomig (Primary) ; Izalontamab brengitecan (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
Most Recent Events
- 23 Nov 2023 Planned End Date changed from 1 Jul 2025 to 1 Nov 2025.
- 23 Nov 2023 Planned primary completion date changed from 1 Jul 2025 to 1 Nov 2025.
- 23 Nov 2023 Status changed from not yet recruiting to recruiting.